PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
Anti-programmed cell death-1 (PD-1)/PD-ligand-1 (PD-L1) treatments are effective in a fraction of patients with advanced malignancies. However, the majority of patients do not respond to it. Resistance to cancer immunotherapy can be mediated by additional immune checkpoints. We hypothesized that co-...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis Group
2021-01-01
|
| Colecção: | OncoImmunology |
| Assuntos: | |
| Acesso em linha: | http://dx.doi.org/10.1080/2162402X.2021.1943180 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|